TotalSeq™-B1453 anti-human CD222 (IGF2R) Recombinant Antibody, CD222 (IGF2R), QA19A18,BioLegend,364209

Host

Mouse

Reactivity

Human

Application

ICPG - Quality tested

Platform ID

BAB501704797

BioLegend

Headquarters

8999 BioLegend Way San Diego, CA 92121 United States

Contact

Tel: 1-858-455-9588
Fax: +49 (4131) 7023913

Email:

Product Specifications
Scientific Background

Specifications

NameTotalSeq™-B1453 anti-human CD222 (IGF2R) Recombinant Antibody, CD222 (IGF2R), QA19A18
Cat. No.364209
HostMouse
RRIDAB_3106218 (BioLegend Cat. No. 364209)
IsotypeMouse IgG1, κ
ReactivityHuman
ApplicationICPG - Quality tested
ClonalityRecombinant
Clone NumberQA19A18
Concentration0.5 mg/mL
TargetCD222
PurityThe antibody was purified by chromatography and conjugated with TotalSeq™-B oligomer under optimal conditions.
FormulationPhosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and EDTA
StorageThe antibody solution should be stored undiluted between 2°C and 8°C.Do not freeze.
Regulatory StatusResearch Use Only

Scientific Background

QA19A18 recombinant antibody binds to CD222 in human, which is also known as the Insulin-like growth factor 2 receptor (IGF2R), cation-independent mannose-6-phosphate receptor (CIMPR), and mannose-6 phosphate receptor (M6PR). CD222 is a type I transmembrane glycoprotein present largely intracellularly in the Golgi apparatus and endosomal compartments, but also at the cell surface. CD222 is expressed ubiquitously in a vast majority of higher eukaryotic cell types and the central component of endosomal transport pathways. The variety of CD222 ligands implicates that CD222 plays important functions in many pathological processes, such as biogenesis of lysosomes, regulation of IGF2, LTGFβ activation, etc. Loss of CD222 is associated with inhibition of T effector cell function.

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.